453 results
8-K
WINT
Windtree Therapeutics Inc
7 Mar 12
Discovery Labs Announces FDA Approval of SURFAXIN® (lucinactant) for Prevention of Respiratory Distress Syndrome
12:00am
, beginning with SURFAXIN and, if approved, its other KL4 surfactant products for RDS: SURFAXIN LS™ and AEROSURF®. The Company’s strategy will focus … . To execute this strategy, the Company expects to incur annual expenses of approximately $12 - $13 million for commercial and medical affairs
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
20 Sep 04
Departure of Directors or Principal Officers
12:00am
to executing our
commercialization strategy. If approved, Surfaxin will represent a significant
opportunity to improve the standard of care …
throughout the world. Our strategy is to build a therapeutic portfolio that
addresses the range of respiratory disorders treated in the NICU, critical
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
7 May 01
Current report
12:00am
extensive mergers and acquisition experience will play an
integral role in helping us realize our strategy of acquiring other synergistic
critical care … establishing a development strategy for its second product,
SuperVent(TM), to treat certain inflammatory respiratory diseases such as
chronic bronchitis
8-K
WINT
Windtree Therapeutics Inc
3 Aug 09
Discovery Labs Provides Second Quarter 2009 Financial Results and Business Strategy Update
12:00am
, 2009 and providing a status update on the Company’s business strategy.
The Company anticipates that its cash outflow for the second half of 2009 … strategy. To secure capital and advance its KL4 surfactant pipeline programs, the Company is seeking to reduce the financial burden on the Company
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
13 Feb 13
Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management
12:00am
in the potential of our transformative technology and business strategy,” commented John G. Cooper, President and Chief Executive Officer at Discovery … strategy to achieve important commercial, development and strategic milestones.”
“We believe that SURFAXIN® and AEROSURF® could represent meaningful
8-K
EX-99.1
a3tpd eas3
26 Oct 06
Entry into a Material Definitive Agreement
12:00am
8-K
0cki2f0nh9nnx
5 Aug 14
Discovery Labs Reports Second Quarter 2014 Financial Results
12:00am
8-K
ovsw44fq
13 Aug 03
Other events
12:00am
8-K
EX-99.2
b8oopxvgubcfoj6
24 Oct 12
Other Events
12:00am
8-K
EX-99.1
dzukkszw0qe0 ar82v
23 Dec 02
Other events
12:00am
8-K
EX-99.1
3iziv7u8
5 Aug 04
Results of Operations and Financial Condition
12:00am
8-K
EX-99.3
e4v xuxx8q
4 Nov 04
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
4n2cuq6heysc
5 Oct 01
Other events
12:00am